Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) and NexGel (NASDAQ:NXGL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
Risk and Volatility
Bluejay Diagnostics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, NexGel has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
Insider & Institutional Ownership
18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 2.2% of NexGel shares are owned by institutional investors. 6.1% of Bluejay Diagnostics shares are owned by company insiders. Comparatively, 23.4% of NexGel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Bluejay Diagnostics | N/A | -144.27% | -115.00% |
| NexGel | -28.54% | -64.29% | -29.64% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Bluejay Diagnostics and NexGel, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bluejay Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
| NexGel | 1 | 0 | 1 | 0 | 2.00 |
NexGel has a consensus target price of $2.00, suggesting a potential upside of 284.69%. Given NexGel’s stronger consensus rating and higher possible upside, analysts clearly believe NexGel is more favorable than Bluejay Diagnostics.
Earnings and Valuation
This table compares Bluejay Diagnostics and NexGel”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bluejay Diagnostics | N/A | N/A | -$6.85 million | ($11.63) | -0.25 |
| NexGel | $11.27 million | 0.43 | -$3.00 million | ($0.40) | -1.30 |
NexGel has higher revenue and earnings than Bluejay Diagnostics. NexGel is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
NexGel beats Bluejay Diagnostics on 9 of the 13 factors compared between the two stocks.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
About NexGel
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
